FDA Accepts Roche’s Filing for Lunsumio VELO-Polivy in LBCL
Roche RHHBY announced that the FDA has accepted its supplemental biologics license application (sBLA) seeking approval of Lunsumio…
Roche FDA accepts Lunsumio-Polivy lymphoma sBLA
Roche (OTCQX:RHHBY) reported that the FDA has accepted a supplemental Biologics License Application…
Roche presents Lunsumio data showing potential across earlier treatment lines in indolent and aggressive lymphomas
F. Hoffmann-La Roche Ltd Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory…